Threshold Pharmaceuticals, Inc (THLD): Opiniones

.... pues hoy con la que esta cayendo no empezo mal 5.19
+0.19 (+3.80%)

5.37 en pre-market. ¿Se habrá pasado el tiempo en que el balcón para rondar a la novia, más que balcón, era línea pintada en el suelo?

THLD

PPHM
el super entra, buena señalhttp://nasdaqlandia.com/pphm-peregrine-pharmaceuticalsla-seguridad-de-un-boleto-premiado-cap-3o-actu04032014.html#comment-102638

Por fin una alegría leñe!!

Perdón era para el foro de farmas usa

Threshold Pharmaceuticals EPS of -$0.13, misses on revenues • 7:08 AM

Threshold Pharmaceuticals (THLD): Q4 EPS of -$0.13.
Revenue of $3.2M (+2.02M% Y/Y) misses by $0.38M.

Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.

"We began 2014 with the first pivotal trial of TH-302 in advanced soft tissue sarcoma fully enrolled, the second pivotal trial in advanced pancreatic cancer being conducted by our partner Merck KGaA well underway, and a third registration program in another solid tumor type expected to commence in the coming months," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "In 2014, we expect the Independent Data Monitoring Committee for the soft tissue sarcoma trial, which monitors patient safety on an ongoing basis, will conduct a planned interim efficacy and safety analysis after 235 events are reported. Because the interim analysis is event-driven, we cannot predict with certainty when the interim analysis will commence, but current projections suggest that the number of events may be reached around mid-year, with the interim analysis to be conducted thereafter. Additionally, the Phase 3 MAESTRO study in advanced pancreatic cancer initiated by Merck KGaA a little over a year ago is currently on track with respect to patient recruitment, and we also look forward to providing more details on the expected third registration program in solid tumors. Regarding earlier-stage trials, including multiple myeloma and glioblastoma, we expect to have more data from the expansion of ongoing studies this year that may further guide strategic investment in additional development opportunities for TH-302."

Fourth Quarter and Year End 2013 Financial and Operational Results

Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively, compared to $2.0 million and $5.9 million for the same periods in 2012, respectively. For the year ended December 31, 2013, we recognized $12.5 million in revenue from the amortization of the aggregate of $110 million in upfront and milestone payments earned in 2013 and 2012 from our collaboration with Merck KGaA. For the year ended December 31, 2012, we recognized $5.9 million in revenue from the amortization of the $67.5 million in upfront and milestone payments earned in 2012 from our collaboration with Merck KGaA. The revenue from the upfront payment and milestone payments earned under the agreement is being amortized over the relevant performance period, rather than being immediately recognized when the upfront payment and milestone are earned or received.

The net loss for the fourth quarter of 2013 was $7.6 million compared to a net income of $28.4 million for the fourth quarter of 2012. Included in the net loss for the fourth quarter of 2013 was an operating loss of $7.8 million and non-cash income of $0.2 million compared to an operating loss of $6.0 million and non-cash income of $34.4 million in the fourth quarter of 2012. The net loss for 2013 was $28.4 million compared to a net loss of $71.1 million in 2012. Included in the net loss for 2013 was an operating loss of $26.0 million and non-cash expense of $2.3 million compared to an operating loss of $20.0 million and non-cash expense of $51.2 million in 2012. The non-cash income or expense is related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense).

Research and development expenses were $8.5 million for the fourth quarter ended December 31, 2013, compared to $6.2 million for the same period in 2012. The increase in research and development expenses, net of reimbursement for Merck KGaA's 70% share of total development expenses for TH-302, was due primarily to a $1.3 million increase in clinical development expenses, a $0.6 million increase in consulting expenses and an increase of $0.4 million in employee related expenses, including a $0.3 million increase in non-cash stock-based compensation expense. Research and development expenses were $29.3 million for 2013, compared to $18.8 million in 2012. The increase in research and development expenses, net of reimbursement for Merck KGaA's 70% share of total development expenses for TH-302, was due primarily to a $6.4 million increase in clinical development expenses, a $1.0 million increase in consulting expenses and an increase of $3.1 million in employee related expenses, including a $1.0 million increase in non-cash stock-based compensation expense.

General and administrative expenses were $2.5 million for the fourth quarter of 2013 versus $1.9 million for the fourth quarter of 2012. The increase in general and administrative expenses was due primarily to an increase in employee-related expenses to support the Company's ongoing collaboration with Merck KGaA, including a $0.1 million increase in non-cash stock-based compensation expense. General and administrative expenses were $9.2 million for 2013 versus $7.1 million in 2012. The increase in general and administrative expenses was due primarily to an increase in employee-related expenses to support the Company's ongoing collaboration with Merck KGaA, including a $0.9 million increase in non-cash stock-based compensation expense.

Non-cash stock-based compensation expense included in total operating expenses was $1.4 million for the fourth quarter of 2013 versus $0.9 million for the fourth quarter of 2012. Non-cash stock-based compensation expense included in total operating expenses was $4.9 million for 2013 versus $3.0 million for 2012. The increase in stock-based compensation expense was due to the amortization of a greater number of options with higher fair values.

As of December 31, 2013 and 2012, Threshold had $82.0 million and $70.8 million in cash, cash equivalents and marketable securities, respectively. The net increase in cash, cash equivalents and marketable securities during 2013 was primarily due to the $42.5 million in milestone payments received from Threshold's collaboration with Merck KGaA and $2.4 million from the exercise of warrants and stock options, partially offset by operating cash requirements for 2013.

Clinical Development Outlook for Company- and Merck KGaA-Sponsored Trials of TH-302

The development plan for TH-302 is designed to investigate its safety and efficacy across a broad range of solid tumors and hematologic malignancies. TH-302 is being developed in therapeutic areas supported by preclinical and clinical data and where there is high unmet need for new anti-cancer agents. To date, TH-302 has been evaluated in more than 1,000 patients with cancer. Threshold anticipates the following development activities related to Company- and Merck KGaA-sponsored clinical trials for TH-302 in 2014:

Planned interim safety and efficacy analysis of the Phase 3 clinical trial in soft tissue sarcoma to be conducted by the Independent Data Monitoring Committee;

Continued enrollment of patients in the Merck KGaA Phase 3 MAESTRO trial in patients with advanced pancreatic cancer;

Initiation of a third registration program of TH-302 in another solid tumor type in partnership with Merck KGaA;

Completion of the dose expansion portion of the Company's Phase 1/2 trial in relapsed or refractory multiple myeloma and initiation of the third portion of the trial to determine preliminary safety and efficacy of TH-302 in combination with a proteasome inhibitor;

Completion of the dose escalation portion of the Company's Phase 1 trial of TH-302 in combination with sunitinib to determine the maximum tolerated dose; and

Continued enrollment of patients in the Company's Phase 2 biomarker trial in advanced melanoma.

.... pero que es lo que se a roto ???? .... los resultados ??

Sin deuda, 82 mill $ en cash y Merck pagando milestones. yo es con lo que me quedo
aqui no se ha roto nada.

va ser que si !!!! ... 5.33 0.00(0.00%) 9:47AM .... volvemos a la normalidad.

Sin duda alguna.
El que se fije en los resultados económicos actualmente está totalmente equivocado.
Hay que esperar a la información que den sobre los ensayos clínicos.
Saludos peña